Safety and efficacy of teneligliptin in Japanese patients with type 2 diabetes mellitus: a pooled analysis of two Phase III clinical studies.
about
Antidiabetic treatment with gliptins: focus on cardiovascular effects and outcomesThe dipeptidyl peptidase-4 (DPP-4) inhibitor teneligliptin functions as antioxidant on human endothelial cells exposed to chronic hyperglycemia and metabolic high-glucose memory.Teneligliptin: a review in type 2 diabetes.DPP-4 inhibitor plus SGLT-2 inhibitor as combination therapy for type 2 diabetes: from rationale to clinical aspects.Pharmacokinetic Characteristics and Clinical Efficacy of an SGLT2 Inhibitor Plus DPP-4 Inhibitor Combination Therapy in Type 2 Diabetes.The efficacy and safety of teneligliptin added to ongoing metformin monotherapy in patients with type 2 diabetes: a randomized study with open label extension.Efficacy and safety of teneligliptin.Long-term safety and efficacy of canagliflozin as add-on therapy to teneligliptin in Japanese patients with type 2 diabetes.Efficacy and safety of teneligliptin add-on to insulin monotherapy in Japanese patients with type 2 diabetes mellitus: a 16-week, randomized, double-blind, placebo-controlled trial with an open-label period.Efficacy and safety of teneligliptin added to canagliflozin monotherapy in Japanese patients with type 2 diabetes mellitus: A multicentre, randomized, double-blind, placebo-controlled, parallel-group comparative study.Efficacy and Safety of Teneligliptin 40 mg in Type 2 Diabetes: A Pooled Analysis of Two Phase III Clinical Studies.Teneligliptin enhances the beneficial effects of GLP-1 in endothelial cells exposed to hyperglycemic conditions.Safety and Efficacy of Teneligliptin in Patients with Type 2 Diabetes Mellitus and Impaired Renal Function: Interim Report from Post-marketing Surveillance.Relationship of Eating Patterns and Metabolic Parameters, and Teneligliptin Treatment: Interim Results from Post-marketing Surveillance in Japanese Type 2 Diabetes Patients.
P2860
Q26785454-1312C84C-6AD0-412F-A52E-5F76E78D7BD0Q33700894-889005D3-F356-4B15-9225-51D72CACC7FCQ38609598-A4CF1BB7-BC3D-409F-B1D5-5ED5AE5E5AAFQ38902321-B14D25A0-A0B3-4D81-A8EE-2FF6253E4812Q39063447-3B15D1A7-F802-4FDB-B37D-D0318654CA91Q40753056-5A731200-E240-4010-A633-27ADF9E75BE4Q42330154-A4FAADBF-F26F-4A61-9711-4087F230DC53Q47148933-126FC413-52A6-4039-B71E-7B487ACD7D53Q48031376-9FF25995-3EA0-4320-AE1A-26D3A8792D04Q48274765-CF1D4BCD-82F8-4D59-B4AA-B12B89D78480Q50050575-6D4D28D1-5C8F-42F8-811E-E16196BCE12AQ50532481-404BF6EE-D36B-4023-90D3-28D690A309EEQ52594764-366ADB67-BACE-4879-AAFB-4AAAE1CB77B5Q55401867-E893201D-427D-401F-99AC-D594CB97C94D
P2860
Safety and efficacy of teneligliptin in Japanese patients with type 2 diabetes mellitus: a pooled analysis of two Phase III clinical studies.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Safety and efficacy of tenelig ...... wo Phase III clinical studies.
@en
type
label
Safety and efficacy of tenelig ...... wo Phase III clinical studies.
@en
prefLabel
Safety and efficacy of tenelig ...... wo Phase III clinical studies.
@en
P2093
P2860
P1476
Safety and efficacy of tenelig ...... wo Phase III clinical studies.
@en
P2093
Fuyuhiko Marubayashi
Hiroaki Iijima
Makoto Katoh
Shoko Yokota
Takashi Kadowaki
P2860
P304
P356
10.1517/14656566.2015.1032249
P407
P577
2015-04-10T00:00:00Z